Intra-Cellular Therapies, Inc.
(NASDAQ GS: ITCI)
Rigrodsky Law, P.A. is investigating Intra-Cellular Therapies, Inc. (“Intra-Cellular”) regarding possible breaches of fiduciary duties and other violations of law related to Intra-Cellular’s agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, Intra-Cellular shareholders will receive $132.00 per share in cash.